| 6527 |
Adult BCG Vaccine Implementation Study- Preparedness assessment |
11/06/2024 |
TB prevention including airborne infection control |
| 6528 |
Adult BCG Vaccine Implementation Study- Suggestive training matrix |
11/06/2024 |
TB prevention including airborne infection control |
| 6539 |
Adult BCG Vaccine Implementation Study- Communication Planning |
11/06/2024 |
TB prevention including airborne infection control |
| 6537 |
Adult BCG Vaccine Implementation Study- Indenting & delivery of vaccines & logistics |
11/06/2024 |
TB prevention including airborne infection control |
| 6538 |
Adult BCG Vaccine Implementation Study- Intensify Monitoring & Supportive Supervision |
11/06/2024 |
TB prevention including airborne infection control |
| 6535 |
Adult BCG Vaccine Implementation Study- Dissemination of guidelines/revised formats/IEC materials |
11/06/2024 |
TB prevention including airborne infection control |
| 6536 |
Adult BCG Vaccine Implementation Study- Track preparation in high-priority districts/blocks |
11/06/2024 |
TB prevention including airborne infection control |
| 6396 |
Adult BCG Vaccination- Adverse event following immunization |
12/06/2024 |
TB prevention including airborne infection control |
| 1611 |
IEC strategies for CHVs |
13/06/2024 |
Advocacy communication and social mobilization |
| 1623 |
Target Audience for ACSM activities |
13/06/2024 |
Advocacy communication and social mobilization |
| 1577 |
Patients' charter for TB care |
14/06/2024 |
Community engagement and call centre |
| 980 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Pre-existing Liver Disease |
14/06/2024 |
DR-TB and PMDT |
| 989 |
Management of DR-TB ADR: Giddiness |
14/06/2024 |
DR-TB and PMDT |
| 990 |
Management of DR-TB ADR: Hematological Abnormalities |
14/06/2024 |
DR-TB and PMDT |
| 991 |
Management of DR-TB ADR: Hypothyroidism |
14/06/2024 |
DR-TB and PMDT |
| 992 |
Management of DR-TB ADR: Arthralgia |
14/06/2024 |
DR-TB and PMDT |
| 994 |
Management of DR-TB ADR: Psychotic Symptoms |
14/06/2024 |
DR-TB and PMDT |
| 997 |
Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity] |
14/06/2024 |
DR-TB and PMDT |
| 998 |
Management of DR-TB ADR: Gynecomastia |
14/06/2024 |
DR-TB and PMDT |
| 1069 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE] |
14/06/2024 |
DR-TB and PMDT |
| 1095 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Treatment Extension |
14/06/2024 |
DR-TB and PMDT |
| 1096 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria |
14/06/2024 |
DR-TB and PMDT |
| 1097 |
Requirements from Institutions for the Establishment of Nodal DR-TB Centre |
14/06/2024 |
DR-TB and PMDT |
| 1119 |
Precautions to Ensure Reliability of a Test for Diagnosis of DR-TB |
14/06/2024 |
DR-TB and PMDT |
| 1232 |
Provisions under the NTEP for the Nodal DR-TB Centre |
14/06/2024 |
DR-TB and PMDT |
| 1785 |
Final Treatment Outcomes of DR-TB Cases |
14/06/2024 |
DR-TB and PMDT |
| 1787 |
Patient Turnaround Time from Identification to Treatment Initiation Relative to the Laboratory Technology Used in DR-TB |
14/06/2024 |
DR-TB and PMDT |
| 1206 |
Laboratory Technicians: Terms of Reference [TORs] at the Intermediate Reference Laboratory |
14/06/2024 |
Laboratory services and management |
| 1218 |
Purpose of Acid Fast Bacilli [AFB] Microscopy under NTEP |
14/06/2024 |
Laboratory services and management |
| 1219 |
Smear Microscopic Examination: Different Grades of Smear Findings |
14/06/2024 |
Laboratory services and management |
